Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2819)	12/12/2012 2:21:45 PM
From: tommysdad	2 Recommendations Read Replies (2) \| Respond to of 3202

Need to be a little careful with how one run's the searches. If memory serves, CYT387 is an old Cytopia molecule. There is a fair amount in the public domain about this molecule (which I can dig out if interested), often reported by competitors. Cytopia also had a "JAK3-selective" series that was selective for JAK3 because they were covalent inhibitors that reacted with an active site cysteine (think: the irreversible BTK inhibitors). From memory, that series was partnered with Novartis but never went anywhere (I may be wrong on that one). Regardless, CYT387 is of a bog-standard kinase inhibitor chemotype, unrelated to INCY & PFE. Unless there is something else YM has that is worth a lot, this seems like a reach to me.